You just read:

Helsinn Announces That Phase 2/3 Pivotal Trials for NEPA (netupitant 300 mg + oral palonosetron 0.50 mg), Will be Published in the Annals of Oncology

News provided by

Helsinn Group

10 Jul, 2014, 11:25 BST